The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Multiple Myeloma Drugs-Global Market Insights and Sales Trends 2025
Synopsis
Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs).
The global Multiple Myeloma Drugs market size is expected to reach US$ 1271.1 million by 2029, growing at a CAGR of 6.2% from 2023 to 2029. The market is mainly driven by the significant applications of Multiple Myeloma Drugs in various end use industries. The expanding demands from the Men and Women, are propelling Multiple Myeloma Drugs market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Corticosteroids segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Multiple Myeloma Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Multiple Myeloma Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Multiple Myeloma Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Multiple Myeloma Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Multiple Myeloma Drugs covered in this report include Amgen, Johnson & Johnson, Celgene, Takeda Pharmaceutical, Novartis, Daiichi Sankyo, Merck, AB Science and Teva, etc.
The global Multiple Myeloma Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
Teva
PharmaMar
Global Multiple Myeloma Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Multiple Myeloma Drugs market, Segment by Type:
Chemotherapy
Corticosteroids
Immunomodulators
Monoclonal Antibodies
Histone Deacetylase (HDAC) Inhibitors
Proteasome Inhibitors
Others
Global Multiple Myeloma Drugs market, by Application
Men
Women
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Multiple Myeloma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs).
The global Multiple Myeloma Drugs market size is expected to reach US$ 1271.1 million by 2029, growing at a CAGR of 6.2% from 2023 to 2029. The market is mainly driven by the significant applications of Multiple Myeloma Drugs in various end use industries. The expanding demands from the Men and Women, are propelling Multiple Myeloma Drugs market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Corticosteroids segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Multiple Myeloma Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Multiple Myeloma Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Multiple Myeloma Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Multiple Myeloma Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Multiple Myeloma Drugs covered in this report include Amgen, Johnson & Johnson, Celgene, Takeda Pharmaceutical, Novartis, Daiichi Sankyo, Merck, AB Science and Teva, etc.
The global Multiple Myeloma Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
Teva
PharmaMar
Global Multiple Myeloma Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Multiple Myeloma Drugs market, Segment by Type:
Chemotherapy
Corticosteroids
Immunomodulators
Monoclonal Antibodies
Histone Deacetylase (HDAC) Inhibitors
Proteasome Inhibitors
Others
Global Multiple Myeloma Drugs market, by Application
Men
Women
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Multiple Myeloma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Multiple Myeloma Drugs Market Overview
1.1 Multiple Myeloma Drugs Product Overview
1.2 Multiple Myeloma Drugs Market Segment by Type
1.2.1 Chemotherapy
1.2.2 Corticosteroids
1.2.3 Immunomodulators
1.2.4 Monoclonal Antibodies
1.2.5 Histone Deacetylase (HDAC) Inhibitors
1.2.6 Proteasome Inhibitors
1.2.7 Others
1.3 Global Multiple Myeloma Drugs Market Size by Type
1.3.1 Global Multiple Myeloma Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Multiple Myeloma Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Multiple Myeloma Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Multiple Myeloma Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Multiple Myeloma Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Multiple Myeloma Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Multiple Myeloma Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Multiple Myeloma Drugs Sales Breakdown by Type (2018-2023)
2 Global Multiple Myeloma Drugs Market Competition by Company
2.1 Global Top Players by Multiple Myeloma Drugs Sales (2018-2023)
2.2 Global Top Players by Multiple Myeloma Drugs Revenue (2018-2023)
2.3 Global Top Players by Multiple Myeloma Drugs Price (2018-2023)
2.4 Global Top Manufacturers Multiple Myeloma Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Multiple Myeloma Drugs Market Competitive Situation and Trends
2.5.1 Multiple Myeloma Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Multiple Myeloma Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Multiple Myeloma Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Multiple Myeloma Drugs Market
2.8 Key Manufacturers Multiple Myeloma Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Multiple Myeloma Drugs Status and Outlook by Region
3.1 Global Multiple Myeloma Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Multiple Myeloma Drugs Historic Market Size by Region
3.2.1 Global Multiple Myeloma Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Multiple Myeloma Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Multiple Myeloma Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Multiple Myeloma Drugs Forecasted Market Size by Region
3.3.1 Global Multiple Myeloma Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Multiple Myeloma Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Multiple Myeloma Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Multiple Myeloma Drugs by Application
4.1 Multiple Myeloma Drugs Market Segment by Application
4.1.1 Men
4.1.2 Women
4.2 Global Multiple Myeloma Drugs Market Size by Application
4.2.1 Global Multiple Myeloma Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Multiple Myeloma Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Multiple Myeloma Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Multiple Myeloma Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Multiple Myeloma Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Multiple Myeloma Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Multiple Myeloma Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Multiple Myeloma Drugs Sales Breakdown by Application (2018-2023)
5 North America Multiple Myeloma Drugs by Country
5.1 North America Multiple Myeloma Drugs Historic Market Size by Country
5.1.1 North America Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Multiple Myeloma Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Multiple Myeloma Drugs Sales in Value by Country (2018-2023)
5.2 North America Multiple Myeloma Drugs Forecasted Market Size by Country
5.2.1 North America Multiple Myeloma Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Multiple Myeloma Drugs Sales in Value by Country (2024-2029)
6 Europe Multiple Myeloma Drugs by Country
6.1 Europe Multiple Myeloma Drugs Historic Market Size by Country
6.1.1 Europe Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Multiple Myeloma Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Multiple Myeloma Drugs Sales in Value by Country (2018-2023)
6.2 Europe Multiple Myeloma Drugs Forecasted Market Size by Country
6.2.1 Europe Multiple Myeloma Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Multiple Myeloma Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Multiple Myeloma Drugs by Region
7.1 Asia-Pacific Multiple Myeloma Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Multiple Myeloma Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Multiple Myeloma Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Multiple Myeloma Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Multiple Myeloma Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Multiple Myeloma Drugs Sales in Value by Region (2024-2029)
8 Latin America Multiple Myeloma Drugs by Country
8.1 Latin America Multiple Myeloma Drugs Historic Market Size by Country
8.1.1 Latin America Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Multiple Myeloma Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Multiple Myeloma Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Multiple Myeloma Drugs Forecasted Market Size by Country
8.2.1 Latin America Multiple Myeloma Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Multiple Myeloma Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Multiple Myeloma Drugs by Country
9.1 Middle East and Africa Multiple Myeloma Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Multiple Myeloma Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Multiple Myeloma Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Multiple Myeloma Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Multiple Myeloma Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Multiple Myeloma Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Amgen
10.1.1 Amgen Company Information
10.1.2 Amgen Introduction and Business Overview
10.1.3 Amgen Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Amgen Multiple Myeloma Drugs Products Offered
10.1.5 Amgen Recent Development
10.2 Johnson & Johnson
10.2.1 Johnson & Johnson Company Information
10.2.2 Johnson & Johnson Introduction and Business Overview
10.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Johnson & Johnson Multiple Myeloma Drugs Products Offered
10.2.5 Johnson & Johnson Recent Development
10.3 Celgene
10.3.1 Celgene Company Information
10.3.2 Celgene Introduction and Business Overview
10.3.3 Celgene Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Celgene Multiple Myeloma Drugs Products Offered
10.3.5 Celgene Recent Development
10.4 Takeda Pharmaceutical
10.4.1 Takeda Pharmaceutical Company Information
10.4.2 Takeda Pharmaceutical Introduction and Business Overview
10.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Takeda Pharmaceutical Multiple Myeloma Drugs Products Offered
10.4.5 Takeda Pharmaceutical Recent Development
10.5 Novartis
10.5.1 Novartis Company Information
10.5.2 Novartis Introduction and Business Overview
10.5.3 Novartis Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Novartis Multiple Myeloma Drugs Products Offered
10.5.5 Novartis Recent Development
10.6 Daiichi Sankyo
10.6.1 Daiichi Sankyo Company Information
10.6.2 Daiichi Sankyo Introduction and Business Overview
10.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Daiichi Sankyo Multiple Myeloma Drugs Products Offered
10.6.5 Daiichi Sankyo Recent Development
10.7 Merck
10.7.1 Merck Company Information
10.7.2 Merck Introduction and Business Overview
10.7.3 Merck Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Merck Multiple Myeloma Drugs Products Offered
10.7.5 Merck Recent Development
10.8 AB Science
10.8.1 AB Science Company Information
10.8.2 AB Science Introduction and Business Overview
10.8.3 AB Science Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 AB Science Multiple Myeloma Drugs Products Offered
10.8.5 AB Science Recent Development
10.9 Teva
10.9.1 Teva Company Information
10.9.2 Teva Introduction and Business Overview
10.9.3 Teva Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Teva Multiple Myeloma Drugs Products Offered
10.9.5 Teva Recent Development
10.10 PharmaMar
10.10.1 PharmaMar Company Information
10.10.2 PharmaMar Introduction and Business Overview
10.10.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 PharmaMar Multiple Myeloma Drugs Products Offered
10.10.5 PharmaMar Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Multiple Myeloma Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Multiple Myeloma Drugs Industrial Chain Analysis
11.4 Multiple Myeloma Drugs Market Dynamics
11.4.1 Multiple Myeloma Drugs Industry Trends
11.4.2 Multiple Myeloma Drugs Market Drivers
11.4.3 Multiple Myeloma Drugs Market Challenges
11.4.4 Multiple Myeloma Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Multiple Myeloma Drugs Distributors
12.3 Multiple Myeloma Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
